Apollo 24|7’s Hospital-to-Digital Healthcare Expansion Strategy

Industry & Competitive Context

India’s healthcare delivery system has historically been built around physical infrastructure hospitals, standalone pharmacies, and diagnostic labs operating largely as separate transactions. Over the past decade, digital health platforms such as Practo, Tata 1mg, PharmEasy, and Netmeds entered this market as pure-play digital intermediaries, focused primarily on online pharmacy and teleconsultation services without owning large-scale physical care infrastructure. These players built their businesses around aggregation and logistics rather than clinical delivery.

Apollo Hospitals Enterprise Limited entered this competitive landscape from a fundamentally different starting point. By the time it built its digital arm, Apollo already operated a large, established hospital network a system built over nearly four decades, comprising roughly 10,000 hospital beds, more than 70 hospitals, around 300 clinics, and close to 4,000 pharmacies, according to statements made by Shobana Kamineni, Executive Vice Chairperson of Apollo Hospitals, in a 2020 conversation published by McKinsey & Company. This meant Apollo’s digital expansion was not a greenfield technology build but an extension of an existing clinical and retail footprint a “hospital-to-digital” strategy rather than a “digital-to-hospital” one.

The competitive significance of this distinction is structural. Pure-play digital health companies in India have had to build trust, clinical credibility, and fulfilment infrastructure from scratch. Apollo’s digital platform, by contrast, could draw on an installed base of doctors, hospitals, and pharmacies, and on decades of brand recognition in Indian healthcare. This gave Apollo a differentiated starting position in a market where consumer trust in telehealth and online pharmacy was still developing.

Brand Situation Prior to Campaign

Prior to the launch of its digital platform, Apollo Hospitals’ consumer-facing brand equity was built almost entirely around physical-world assets: multi-specialty hospitals, a pharmacy retail chain, and diagnostic centres. The company’s pharmacy network alone, as described by Kamineni, reached roughly 45% of India’s population within a 30-minute radius, spread across close to 500 towns and cities. However, this reach existed primarily as offline retail infrastructure, not as an integrated digital consumer experience. Patients engaging with Apollo typically interacted with its hospitals, clinics, or pharmacy outlets as discrete touchpoints, without a unified digital record or omnichannel pathway connecting consultation, diagnostics, medicine delivery, and follow-up care.

Apollo 24|7 was launched on February 5, 2020 notably just about a month before India’s nationwide COVID-19 lockdown as a digital healthcare initiative incubated within the Apollo Hospitals group. Its nationwide rollout was formally announced on March 1, 2021, in a joint announcement with Microsoft, which described the platform as built on Microsoft Azure infrastructure, including Azure Database for PostgreSQL, Azure Kubernetes Service, Azure DevOps, and Azure Communication Services for chat, voice, video, and messaging.

Strategic Objective

Apollo’s stated strategic intent, as articulated by Kamineni in the McKinsey interview, was to build an integrated healthcare ecosystem in which patients could access consultations, medicines, and diagnostics through either virtual or physical channels, with health records unified across both. Her explicit framing “the healthcare model can never be just virtual” positioned Apollo 24|7 not as a replacement for its hospital network but as a digital extension and connective layer across it. The objective was omnichannel integration: using the existing hospital, clinic, and pharmacy footprint as the backbone for a digital consumer platform, rather than building a standalone telehealth app disconnected from physical care delivery.

Kamineni also described a deliberate orientation toward patient lifetime value over short-term, discount-led customer acquisition, stating that the model was not built on “discounts driving customers” but on sustained engagement medication reminders, refills, access to new medicines, and ongoing monitoring of chronic conditions such as diabetes and blood pressure. This reflects a strategic choice to compete on continuity of care and brand trust rather than on price competition with pure-play e-pharmacy entrants.

Campaign Architecture & Execution

Apollo 24|7’s execution centred on consolidating multiple healthcare services into a single digital platform, accessible via web and mobile application. Per Apollo and Microsoft’s joint 2021 announcement, the platform’s core service architecture included round-the-clock virtual consultations with Apollo-affiliated doctors (claimed availability within 15 minutes), online medicine ordering with a stated two-hour delivery promise in select cities, online diagnostic test booking with doorstep sample collection, personal health records, a mental health screening tool, and condition management features. During the COVID-19 period specifically, the platform added a cough and risk scanner, post-COVID care support, and vaccine information tools. Apollo ProHealth, described as a preventive health management programme, was also offered through the platform. At the time of the March 2021 announcement, additional features an AI-based health predictor, “wellbeing partner” offerings, and targeted health insurance programmes were described as planned but not yet live.

A parallel and operationally significant execution initiative during the pandemic was Apollo’s “Kavach” project, which Kamineni described as integrating 2,500 hospital beds and 2,000 hotel beds, together with home-care services, into a COVID-19 response effort that she characterised as the largest private-sector initiative of its kind in India at that time. Apollo also participated in a broader industry coalition that launched a nationwide telemedicine platform for COVID-19 care, alongside government-led digital health initiatives such as eSanjeevani (promoted by India’s Ministry of Health) and the Aarogya Setu contact-tracing application.

On the supply side, Apollo’s execution emphasised rapid clinician onboarding: according to Kamineni, the company brought on 3,000 doctors within the first 60 days of the platform’s launch, and by the time of her 2020 interview, Apollo reported more than 7,000 physicians and over 30,000 other healthcare professionals associated with the ecosystem. The March 2021 Microsoft announcement cited similar scale figures over 7,000 doctors across 55-plus specialties, more than 4,000 pharmacy stores, and medicine delivery coverage across 15,000 PIN codes.

Organisationally, Apollo’s execution also involved cross-functional integration between its digital and physical retail operations. Kamineni specifically noted that Apollo’s pharmacy CEO was directly involved in Apollo 24|7 activities, a structural choice intended to ensure the pharmacy network’s operational commitment to the platform’s delivery promises.

Positioning & Consumer Insight

Apollo 24|7 was positioned as an integrated, trust-led alternative to narrower digital health offerings, built on the premise that Indian consumers particularly during the pandemic needed a single platform combining consultation, diagnostics, and medicine access, backed by an established clinical brand. Kamineni’s framing that “patients choose our brand and they use our doctors” reflects a positioning strategy anchored in institutional credibility rather than price or pure convenience. The underlying consumer insight, as Apollo articulated it, was that Indian patients wanted continuity between virtual and physical care the ability to begin a health interaction digitally and complete it, when necessary, within Apollo’s existing hospitals, clinics, or pharmacies, with a unified medical record connecting both.

The adoption data Apollo shared supports this positioning thesis to some extent: roughly six months after launch, the platform reported 4 million enrolled users and approximately 30,000 downloads per day, with around 25% of users returning on a weekly basis, according to Kamineni’s 2020 remarks. These figures, however, are company-disclosed and were not independently verified by McKinsey or any third party in the published interview, and no comparable platform-specific user or engagement figures appear to have been disclosed by Apollo in its subsequent public filings.

Media & Channel Strategy

Public disclosures reviewed for this case company press materials, the Microsoft partnership announcement, and the McKinsey interview describe platform features, technology infrastructure, and clinician/pharmacy scale, but do not disclose marketing budgets, advertising channels, or performance marketing data. Any claims about Apollo 24|7’s specific media strategy beyond what is stated above would be speculative and are therefore excluded from this case study.

Business & Brand Outcomes

Apollo’s digital and pharmacy distribution operations have since evolved into a distinct, increasingly formalised business unit within the Apollo Hospitals group, with several outcomes becoming visible through investor disclosures and corporate transactions rather than consumer marketing metrics.

In April 2024, Apollo HealthCo Limited the subsidiary housing Apollo’s digital health and pharmacy distribution businesses agreed to raise ₹2,475 crore from private equity firm Advent International. The transaction valued Apollo HealthCo at ₹14,478 crore and Keimed Private Limited, a pharmaceutical distributor being integrated into the group’s supply chain, at ₹8,003 crore, implying a combined entity valuation of approximately ₹22,481 crore. Under the agreed structure, Advent was set to hold a 12.1% stake in the combined entity, with Keimed’s existing shareholders holding approximately 25.7% following the merger, and Apollo Hospitals Enterprise Limited retaining majority ownership.

On June 30, 2025, Apollo Hospitals announced a more significant corporate restructuring: a plan to demerge its omnichannel pharmacy distribution business, Apollo 24|7, and its remote telehealth division into a newly created, separately listed entity, with Apollo HealthCo and Keimed to be merged into this new company. The announced rationale, per the company’s investor communication, was to unlock shareholder value, sharpen operational focus, and create a unified listed digital health and pharmacy platform, while removing the “holding company discount” historically applied to the digital and pharmacy business when embedded within the broader hospital entity. Under the announced share-exchange terms, existing Apollo Hospitals shareholders would receive 195.2 shares of the new entity for every 100 Apollo Hospitals shares held, with Apollo Hospitals retaining an estimated 15–17.5% stake and board representation in the new company. The new entity was expected to list within 18 to 21 months of the announcement, subject to regulatory and legal approvals; in September 2025, the Competition Commission of India cleared the group’s related restructuring plan. Financial projections disclosed as part of this announcement indicated expected FY2025 revenue for the new entity of approximately ₹16,300 crore, EBITDA of about ₹580 crore, and net profit of around ₹220 crore, with a stated FY2027 target of ₹25,000 crore in revenue and an EBITDA margin of approximately 7%. As part of the broader restructuring, Keimed was described as holding roughly 15% share of India’s medicine distribution market, and Apollo’s pharmacy network had grown to more than 6,600 physical stores up from the roughly 4,000 stores cited at the time of Apollo 24|7’s 2021 nationwide launch. Apollo Hospitals’ share price rose 3.48% to ₹7,495 on the day the demerger plan was announced.

More recently, in quarterly results covering the July–September 2025 period (Q2 FY26), Apollo Hospitals reported that its Digital Health & Pharmacy Distribution segment generated revenue of ₹2,282.2 crore, representing year-on-year growth of 17%, with company commentary attributing the performance to “expanded reach and customer trust” in its digital platforms. No verified public information is available on Apollo 24|7’s current registered user base, consultation volumes, or order volumes beyond the 2020-era figures disclosed in the McKinsey interview; the company does not appear to have published updated platform-level user metrics in its subsequent investor disclosures reviewed for this case.

Strategic Implications

Apollo 24|7 illustrates a distinct model of digital health expansion in emerging markets: rather than a technology company attempting to build trust and clinical infrastructure from zero, an established hospital operator extended its existing physical assets doctors, beds, pharmacies, and brand equity into a unified digital channel. This hospital-to-digital sequencing appears to have provided Apollo with two structural advantages documented in the public record: an ability to onboard clinical supply (thousands of doctors) rapidly by drawing on an existing physician network, and a fulfilment backbone (nearly 4,000, later over 6,600, pharmacy outlets) that pure-play digital entrants would have needed to build or partner for independently.

The subsequent corporate actions the 2024 private equity investment from Advent International and the 2025 demerger announcement suggest that Apollo’s digital and pharmacy distribution business matured from an internally incubated initiative into a standalone entity capable of attracting independent institutional capital and, eventually, a separate public listing. The stated rationale for the demerger, centred on eliminating a “holding company discount” and enabling direct market comparison with other digital health and pharmacy businesses, indicates that Apollo’s own leadership came to view the digital arm as having outgrown its original role as an ancillary channel within the hospital business, instead becoming a distinct, separately valuable enterprise.

At the same time, the publicly available record leaves clear gaps relevant to any assessment of long-term digital strategy success namely, the absence of disclosed, updated platform-level metrics (active users, retention, consultation or order volumes) since the 2020 figures shared in the McKinsey interview. This limits the extent to which Apollo 24|7’s standalone digital traction, as distinct from its pharmacy distribution revenue, can be independently assessed from public sources. The documented outcomes to date are primarily financial and structural revenue growth in the combined digital health and pharmacy segment, and a path toward independent capital markets access rather than platform-engagement outcomes.

Discussion Questions

1. What are the structural advantages and risks of an established hospital network building its digital health platform as an internal extension of physical infrastructure, compared with a pure-play digital health start-up building clinical trust from scratch?

2. Apollo’s leadership described a deliberate emphasis on patient lifetime value over discount-led acquisition. What are the trade-offs of this positioning in a market where competitors have historically used aggressive pricing to acquire customers?

3. How does the 2025 demerger of Apollo’s digital and pharmacy business into a separately listed entity change the strategic and governance relationship between the hospital business and the digital platform, and what risks does this separation introduce for the “hybrid physical-virtual” care model Apollo had originally emphasised?

4. Given the limited public disclosure of platform-level engagement metrics (active users, retention, consultation volumes) since 2020, what does this suggest about how investors and analysts should evaluate the digital health segment’s standalone performance ahead of a planned IPO?

5. What lessons can other hospital-led or asset-heavy healthcare providers draw from Apollo’s approach to integrating existing clinical and retail infrastructure into a digital consumer platform, particularly regarding the sequencing of technology partnerships, clinician onboarding, and eventual corporate restructuring?